Eagle’s Eye View: Race and Sex Disparities in Mitral Valve Edge-to-Edge Repair
In this week’s View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men. He reviews the SOGALDI-PEF trial, where patients with low plasma renin levels experienced greater blood pressure reduction with spironolactone/dapagliflozin compared to dapagliflozin alone. Next, he discusses the FAVOR III trial, which found that QFR-guided percutaneous coronary intervention improved five-year outcomes versus angiography guidance, with most benefits occurring in the first two years. Lastly, Dr. Eagle examines two renal disease studies addressing optimal chronic kidney disease (CKD) GFR thresholds and the benefits of finerenone in CKD patients.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Cardiovascular Care Team, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Valvular Heart Disease, Lipid Metabolism, Novel Agents, Acute Heart Failure, Interventions and Imaging, Interventions and Structural Heart Disease, Angiography, Nuclear Imaging, Hypertension, Mitral Regurgitation
Keywords: EaglesEyeView, National Cardiovascular Data Registries, STS/ACC TVT Registry, Mitral Valve Insufficiency, Delivery of Health Care, Heart Failure, Mineralocorticoids, Blood Pressure, Hypertension, Aldosterone, Spironolactone, Renin, Percutaneous Coronary Intervention, Angiography, Renal Insufficiency, Renal Insufficiency, Chronic, Rivaroxaban
